CASI Pharmaceuticals Files 6-K Report
Ticker: CASIF · Form: 6-K · Filed: Apr 15, 2026
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer
TL;DR
CASI Pharma filed a 6-K on 4/15/26, standard foreign issuer report from Beijing.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 15, 2026, reporting information as a foreign issuer. The filing includes standard documents and details the company's mailing and business addresses in Beijing, China.
Why It Matters
This filing provides routine updates for CASI Pharmaceuticals, Inc. as a foreign issuer, which is important for investors tracking the company's compliance and operational information.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the 6-K report
- 0001962738 (company) — CIK number for CASI Pharmaceuticals, Inc.
- 2026-04-15 (date) — Filing date and period of report
FAQ
What type of filing is this?
This is a Form 6-K, a Report of foreign issuer.
When was this filing made?
The filing date was April 15, 2026.
Who is the filer?
The filer is CASI Pharmaceuticals, Inc.
Where is CASI Pharmaceuticals, Inc. located?
The company's mailing and business addresses are in Beijing, China.
What is the CIK number for CASI Pharmaceuticals, Inc.?
The CIK number is 0001962738.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2026 regarding CASI Pharmaceuticals, Inc. (CASIF).